Jacques Troncy

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Thierry Façon, Jean Yves Mary, Cyrille Hulin et al. · The Lancet · 2007 · 870 citations

Hematological Malignancy, Cell Therapy, Transplantation +14

Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis [see comments]

Lydia Campos, Denis Guyotat, E Archimbaud et al. · Blood · 1992 · 495 citations · Full text

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

Jean‐Luc Harousseau, Michel Attal, Xavier Leleu et al. · PubMed · 2006 · 335 citations

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial

Natacha Heutte, Hans‐Henning Flechtner, Nicolas Mounier et al. · The Lancet Oncology · 2009 · 103 citations

Quality Of Life, Lymphoid Neoplasia, 10-Year Follow-up +6

Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma.

Thierry Façon, Jean–Yves Mary, C. Hulin et al. · Blood · 2005 · 65 citations